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ABSTRACT 
 
Objective: To assess the long-term effectiveness and safety of IL1Ra in Schnitzler syndrome 
(SchS).  
Methods: Between 2010 and 2012, we performed a nationwide survey among French internal 
medicine departments to identify SchS patients. We retrospectively analyzed the long-term 
efficacy and safety of IL1Ra and the outcome of patients that did not receive this treatment. 
Results: Forty-two patients were included in the study, 29 of whom received IL1Ra. The 
mean age at disease onset was 59.9 years. Disease manifestations included urticaria (100%), 
fever (76%), bone/joint pain (86%), bone lesions (76%), anemia (67%), and weight loss 
(60%). The monoclonal gammopathy was overwhelmingly IgM kappa (83%). The mean 
follow-up was 9.5 years (range: 1.6–35). Two patients developed Waldenström’s 
macroglobulinemia and one developed AA amyloidosis. All of the 29 patients who received 
IL1Ra responded dramatically. After a median follow-up of 36 months (range: 2–79), the 
effectiveness remained unchanged. All patients remained on anti-IL-1 therapy. Twenty-four 
patients (83%) went into complete remission and five (17%) into partial remission. Three 
patients experienced grade 3–4 neutropenia. Six patients developed severe infections. No 
lymphoproliferative diseases occurred while on IL1Ra. When last seen, all patients without 
anakinra had an active disease with variable impact on their quality of life. Their median 
corticosteroids dosage was 6 mg/d (range: 5–25). 
Conclusions: IL1Ra is effective in SchS, with a sharp corticosteroid-sparing effect. 
Treatment failures should lead to reconsider the diagnosis. Long-term follow-up revealed no 
loss of effectiveness and a favorable tolerance profile. The long-term effects on the risk of 
hemopathy remain unknown. 
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1. Introduction 
 Schnitzler's syndrome (SchS) is a rare disease that manifests with a urticarial skin 
rash, monoclonal gammopathy (mostly IgM kappa), and a variable combination of recurrent 
fever, osteoarticular pain, sclerotic bone lesions, lymphadenopathy, and hepatosplenomegaly 
[1,2] This disease was first described by the French dermatologist Liliane Schnitzler almost 
40 years ago (3,4), but even today it is still underdiagnosed [5]. 
 Patients with SchS frequently exhibit an altered quality of life (QoL) because of 
recurrent fever, rash, pain, fatigue, and sometimes weight loss or anemia [1,2]. As with other 
patients with monoclonal gammopathy of undetermined significance, SchS patients may 
develop a hematological malignancy (usually Waldenström's macroglobulinemia). More 
infrequently, they can develop AA amyloidosis [6,7]. Conventional therapies, such as 
antihistamines, non-steroidal anti-inflammatory drugs (NSAID), corticosteroids, 
immunomodulating agents (colchicine and hydroxychloroquine), and pefloxacin, usually 
provide only partial or transient improvement of the symptoms [7]. Disease-modifying anti-
rheumatic drugs are rarely useful [2,7]. In recent years, several case reports have revealed the 
remarkable efficacy of the interleukin-1 (IL-1) receptor antagonist (IL1Ra) anakinra on this 
disease [8,9]. Two small, open-label, non-comparative studies also demonstrated the short-
term efficacy of the long-acting IL-1 blockers canakinumab [10] and rilonacept [11]. Given 
the efficacy of blocking IL-1 activity towards treatment of this disease, phenotypical 
similarities between SchS and cryopyrin-associated periodic syndrome, and biological data 
suggesting a dysfunction of the inflammasome [11-15], most physicians and scientists 
consider SchS an acquired, late-onset auto-inflammatory disease [1,2,7,16]. However, the 
relationship between the systemic inflammation and the monoclonal component remains 
unknown. 
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 Unfortunately, most data regarding the use of IL1Ra in SchS arise from case reports or 
very small study series. Therefore, long-term data regarding its efficacy, tolerance, and safety 
are scarce. Furthermore, the concern that some patients may not respond to IL-1 blockers has 
recently emerged [17,18] and the possibility of secondary treatment failure remains unknown 
(2). 
 Herein we report on the long-term effectiveness and safety of the off-label use of 
IL1Ra in SchS through a retrospective analysis of a multicenter cohort of 42 patients with 
SchS, of whom 29 were treated with IL1Ra. 
 
2. Patients and Methods  
2.1. Patients 
 In this study, we included all of the SchS patients evaluated at Nantes University 
Hospital since 1998 (n = 17). Further, we conducted a nationwide survey among all of the 
departments of internal medicine in France through the French Internal Medicine Society 
(Société Nationale Française de Médecine Interne) from 2010 to 2012. To be included, 
patients had to fulfill the diagnostic criteria proposed by Lipsker et al. in 2001 [19], 
irrespective of the recourse or the effect of IL-1 blockers. This observational study was 
performed in accordance with the Helsinki declaration, European and French ethical laws. 
 
2.2. Data collection 
 Data were collected from charts using a standardized form that included the following 
information: gender, month/year of birth, date of first symptoms and diagnosis, disease 
manifestations, bone and thoracoabdominal imaging findings, previous therapies, significant 
comorbidities, clinico-biological features, concomitant treatments at the onset of IL1Ra use 
and at the last follow-up, secondary IL1Ra treatment failures, flare-ups following drug 
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interruption or tapering, IL1Ra withdrawal and its reason(s), severe infections (requiring 
hospitalization), injection site reactions, neutropenia and any other IL1Ra adverse effects, 
solid or hematologic malignancy, death and cause of death. 
 
2.3. Disease activity measurement and response to IL1Ra 
 Physician assessment of SchS clinical activity was recorded using a semi-quantitative 
scale for skin rashes, pain, and fever (absent/rare-moderate/frequent-severe). Moderate and 
severe anemia was defined as 10–12 and <10 g/dL hemoglobin levels, respectively. Complete 
remission was defined as the disappearance of all clinical signs of disease activity (rash, fever, 
and pain) under IL1Ra monotherapy. Partial remission was defined based on the improvement 
of at least 50% of the SchS symptoms and systemic inflammation under IL1Ra treatment with 
persistence of over one sign of disease activity among the following: rash, pain, fever, and 
elevated C-reactive protein (CRP; >10 mg/L). For the longitudinal analysis of the monoclonal 
component level, all of the serum electrophoreses of patients followed at Nantes University 
Hospital were re-analyzed using a standard computer-assisted method. 
 
2.4. Data Analysis 
 Categorical variables were expressed as percentages and compared using chi-squared 
tests or Fisher’s exact tests, as appropriate. For quantitative variables, comparisons of 
independent groups and paired measurements were performed using the non-parametric 
Mann-Whitney tests and Wilcoxon signed-rank tests, respectively. Data analysis was 
performed using GraphPad Prism 4.02 software (GraphPad; San Diego, CA, USA). All tests 
were two-sided and a p <0.05 was considered statistically significant. 
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3. Results 
3.1. Cohort characteristics 
 The cohort included 42 SchS patients from 16 centers. There were 30 men and 12 
women. The mean age at disease onset was 59.9 ± 11.9 years (range : 34–79). The mean 
diagnostic delay was 43 ± 36 months (range: 1–141). 
 Aside from the urticarial rash, fever and bone and joint pain were the most frequent 
complaints (Table 1). In addition, 25 patients experienced weight loss and 28 developed 
inflammatory anemia, with a hemoglobin level at <10 g/dL in 16 cases (38%). 
 Overall, 29 patients were treated with corticosteroids (69%), 26 received an 
immunomodulating agent (62%), 13 received an immunosuppressant or an alkylating agent 
(31%), and 3 received a non anti-IL1 biologic (7%). Twenty-nine patients were treated with 
IL1Ra (69%). The details on each treatment are reported in Table 2. 
 The mean follow-up was 9.5 years (range: 1.6–35). Two patients progressed toward a 
hematologic malignancy (Waldenström’s macroglobulinemia), three and nine years after the 
first SchS symptoms (age: 63 and 75 years). One untreated patient developed renal AA 
amyloidosis. Four patients died (Table 3). 
 
3.2. Patients treated with IL1Ra 
 Twenty-nine patients were treated with IL1Ra: 20 men and 9 women. At IL1Ra 
introduction, the mean age was 65.9 ± 10.7 years (range: 44–85) and mean disease duration 
was 7.5 ± 6.9 years (range: 10 months to 32 years). One patient received IL1Ra as a first-line 
therapy. Four patients received only symptomatic drugs (NSAID or antihistamines) prior to 
IL1Ra treatment. Twenty-four patients had failed at least one immunomodulating (n = 20), 
immunosuppressive (n = 11), or non anti-IL1 biologic (n = 3) treatment. Twenty-one patients 
received corticosteroids (72%). 
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 From a clinical standpoint, all of the patients had an active disease at the point of 
IL1Ra introduction (Figure 1). All of them suffered recurrent or chronic skin rash, and 22 had 
severe extracutaneous symptoms (fever and/or bone pain; 76%). The remaining seven patients 
had no or moderate extracutaneous symptoms but severe anemia (n = 1), significant weight 
loss (n = 4), and/or fatigue (n = 3). Fifteen patients were corticodependant and their mean 
corticosteroid dose was 13.6 ± 8.4 mg/d of the equivalent prednisone (median: 10 mg/d) and 
the mean duration of corticosteroid therapy was 3.1 ± 3 years (range: 0.5–12.8). In addition, 
one patient with a long-standing (12 years) untreated IgM kappa SchS developed AA 
amyloidosis, which was revealed by nephrotic-range proteinuria (3–3.5 g/day). Amyloid 
deposits were discovered and typed using immunofluorescence, both with colon and 
accessory salivary gland biopsies. 
 
3.3. Initial and long-term effectiveness of IL1Ra 
 All 29 treated patients experienced a dramatic improvement in all of the clinical signs 
of disease activity within 48 h after IL1Ra introduction, which enabled discontinuation of the 
concomitant therapies. Only three patients were maintained on low-dose corticosteroid 
therapy in order to alleviate residual symptoms. 
 After a median follow-up of 36 months (range: 3–79), the effectiveness of IL1Ra was 
unchanged. At the last follow-up under IL1Ra (Figure 1), 24 patients (83%) were in complete 
remission under IL1Ra monotherapy. Three had mild residual bone pain. Five patients (17%) 
were in partial remission. Among these, three were asymptomatic with normal CRP under 
IL1Ra treatment plus low-dose corticosteroids and two patients had intermittent skin rash and 
pain with normal CRP under IL1Ra monotherapy. The CRP level returned to normal in all of 
the patients in complete clinical remission, except one (Figure 2). The mean hemoglobin level 
rose from 11.2 to 13.4 g/dL (p <0.001). Only one patient was switched to canakinumab 
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because he was in partial remission and experienced injection site reaction under IL1Ra. 
Canakinumab was well tolerated and maintained a comparable state of partial remission. For 
nineteen of the patients, IL1Ra injections were spaced out. Injections were done on alternate 
days; however, complete clinical remission was maintained in only four cases. Other patients 
had to resume back to daily injection. 
 Anakinra had no effect on the level of the IgM kappa monoclonal component (Figure 
3). Of note, the latter was frequently present at a very low level. 
 
3.4. Long-term tolerance and safety of IL1Ra 
 Injection site reactions were reported in five patients (17%). All of them could 
continue with the treatment. Six patients experienced severe infections, including one case of 
a severe sore throat and five cases of pneumonia. Importantly, among the patients that 
developed pneumonia, four out of the five had predisposing factors (three had severe chronic 
obstructive pulmonary disease (COPD) and one had dementia and parenteral feeding), aside 
from IL1Ra. The pneumonia was fatal in two of these cases. Three cases of uncomplicated 
neutropenia were recorded. In one patient, it did not recur after adjusting the IL1Ra dosage to 
weight (30 kg). In another patient, the neutrophil count normalized and complete remission 
persisted under alternate day injections. In the third case, neutropenia occurred on two 
occasions within 48 hours after IL1Ra introduction, but it did not recur on the third attempt. 
 One patient under IL1Ra treatment developed colon cancer during the follow-up. 
However, six other malignancy or pre-malignant states were observed in four patients that had 
not received IL1Ra at that time (colon, prostate, bladder, kidney, colon adenoma, and basal 
cell carcinoma).  
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3.5. Outcome of IL1Ra-naive patients 
 Thirteen patients did not receive IL1Ra treatment. Overall, disease manifestations 
were similar to that of patients that received IL1Ra, except for pain, which tended to be less 
frequent (Table 1). Clinical information at the last follow-up was available for 12 patients. All 
of them still harbored an active disease or had their disease controlled with corticosteroids. 
Eight patients were treated with corticosteroids (median dose: 6 mg/day; range: 5–25). Except 
for two patients, all of the cases had elevated CRP levels (median: 29.6 mg/L). Two patients 
received colchicine and one received chloraminophene. Compared to the patients that were 
treated with IL1Ra, the disease duration was comparable (median = 97 vs. 110 months, p = 
0.11), but the IL1Ra-treated patients had less severe symptoms and biological abnormalities 
(Figures 1 and 2). 
 
4. Discussion  
 In this study we assessed the long-term effectiveness, tolerance, and safety of IL1Ra 
treatment in patients with SchS. To the best of our knowledge, this is the largest series 
focusing on the management of these patients since the advent of IL-1-targeted therapies.  
 A wide range of drugs has been used in patients with SchS [2,7,20]. However, none of 
these treatments were reported to induce a complete, durable remission of the disease until the 
first report of the successful use of IL1Ra [8]. Since then, numerous case reports have 
confirmed this observation [2,9]. The present series confirmed the dramatic efficacy of IL1Ra 
in SchS, which appeared to be constant in our patients. Several authors have suggested that 
the response to IL1Ra treatment could be used as a diagnostic criterion [1]. However, we did 
not use this criterion in our study because we wanted to assay any cases of primary IL1Ra 
failure, which we did not observe in our patients. Therefore, we strongly believe that failures 
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in IL1Ra treatment should lead to a reconsideration of the diagnosis of SchS. Nevertheless, 
some authors have reported cases of primary failure of IL1Ra treatment. Krause et al. reported 
on three patients that were refractory to IL-1 blockers but responded to tocilizumab [17]. In a 
recent series, 5 out of 20 cases from the Mayo Clinic that received IL1Ra had mixed 
results: three were lost in the follow-up, one experienced a dramatic response, and one saw 
only minimal effects [18]. Therefore, it remained unclear whether the efficacy of IL1Ra was 
overestimated from publication bias or whether some cases were resistant to IL1Ra, which 
may represent a variant of the disease. 
 In this regard, one should note that in the three cases of IL1Ra-resistant cases reported 
by Krause et al., several atypical features were present [17]. First, in two of the cases, the 
gammopathy was not IgM kappa, even though this gammopathy isotype is a major indication 
of SchS [5]. Second, no data were provided on the bone imaging of these three patients. In our 
experience, and that of others [21], bone lesions are highly prevalent in SchS, provided that 
appropriate imaging techniques are used aside from conventional radiographs (i.e. 
technetium-99 (Te99) bone scan). Third, two patients were reported to suffer from recurrent 
ocular inflammation, which is not a typical feature of bona fide SchS. Indeed, we encountered 
only one patient that developed a single ocular inflammation in our study. Altogether, these 
elements, along with our findings, suggest that IL1Ra refractory patients are exceedingly rare 
and that they may represent a variant of SchS. Indeed, one may speculate that some 
gammopathy-associated systemic diseases have yet to be characterized. Longhurst et al. 
recently described a patient with a long-standing history of urticaria, monoclonal 
gammopathy, recurrent fever, cytopenia, and complement activation that was resistant to 
IL1Ra, which may represent a new gammopathy-associated autoinflammatory syndrome [22]. 
 Until now, the accumulated evidence was scarce regarding the long-term outcome of 
patients with SchS that were treated with IL1Ra. Approximately 40 individual cases of 
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
 12 
IL1Ra-responsive SchS have been reported worldwide, with a median follow-up of only 12 
months [2,8,9,15,16,23-27]. In the present study, the median follow-up under IL1Ra treatment 
was three years and 11 patients were treated for more than four years. Our study revealed no 
loss in the effectiveness of the treatment and an adequate tolerance profile. Importantly, our 
data show that anakinra has a major corticosteroid sparing effect. Overall, the long term 
effectiveness and therapeutic maintenance of IL1Ra in SchS seems to be superior to what has 
been reported in other rheumatic diseases that could benefit from this drug, namely 
rheumatoid arthritis [28], adult-onset Still’s disease (AOSD) [29-31]. This is reminiscent of 
its efficacy in inherited auto-inflammatory syndromes [32]. Our series also enlightens the 
safety profile of long term off-label use of IL1Ra, which efficacy has been reported in various 
non-rheumatic adult-onset inflammatory diseases [33,34]. 
 The patients’ tolerance to IL1Ra injections was rather unexpected. Indeed, only one 
was switched to a long-acting anti-IL-1. This finding suggests that the impressive clinical 
benefits experienced by most of our patients clearly outweigh the restrictive nature of daily 
injections. However, a few patients considered treatments that required daily injections were 
not worth the impact to their QoL and therefore decline to recourse to IL1Ra.  
 Severe infections were observed in six of the patients treated with IL1Ra (20%). This 
figure is consistent with the findings of Laskaris et al. in patients with AOSD: among 25 
patients treated with IL1Ra for a median duration of 15 months, 28% developed an infection 
[31]. However, another series with 28 AOSD patients receiving a prolonged IL1Ra treatment 
recorded no serious infections [29]. These discrepancies could be explained by the longer 
follow-up of our series and the older age of the patients with SchS compared to AOSD. 
Moreover, most of our cases had additional predisposing factors to severe infections. Indeed, 
four out of six patients that experienced a severe infection were steroid-dependent before the 
recourse to IL1Ra treatment and had previously received high corticosteroid doses (>7.5 mg/d 
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of prednisone). However, the outcome was fatal in two cases and it cannot be stated whether 
the same would have occurred in the absence of blocking IL-1Ra. On the other hand, pursuing 
high dose corticosteroids in these patients would have probably also carried a significant risk 
of infection. Therefore, clinicians should heed caution and remember that IL1Ra could 
increase the risk of severe infections [35,36]. Another matter of concern was the risk of 
IL1Ra-induced neutropenia. Only three cases were recorded and none developed an infection. 
Interestingly, the adjustment of the therapeutic scheme circumvented this side effect and 
allowed continuation of the treatment in all cases. 
 Aside from the impaired QoL and the side effects of long-term corticosteroid use, the 
main long-term threat to SchS patients is development of a hematologic malignancy (mainly 
Waldenström’s macroglobulinemia) [1,2,7,18,37]. In our patients, only two cases of 
hematologic malignancies were observed, both in IL1Ra-untreated patients. Further studies 
are needed to determine whether IL-1 blockers modify this risk, which has been estimated to 
be 15% at 10 years [7]. In this regard, our finding that blocking IL-1 had no significant effect 
on the monoclonal component is reassuring. 
 In our study we encountered one patient that developed AA amyloidosis. This patient 
suffered from SchS for more than ten years before he developed proteinuria. However, his 
symptoms had no major impact on his daily living. Therefore, he was reluctant to receive any 
medication. IL1Ra treatment induced a complete remission of SchS, but after 12 months of 
follow-up, the proteinuria had not improved. AA amyloidosis is a key complication of bona-
fide inherited autoinflammatory diseases [38], but little is known regarding patients with 
SchS. To our knowledge, only three cases of SchS-related AA amyloidosis have been 
reported in the literature [6,7]. Some clinicians reckon that this threat warrants complete 
control of inflammation in every single patient with SchS. 
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 Our work has the intrinsic limitation associated with retrospective studies and is not 
free from certain biases. For example, since the patients were recruited from internal medicine 
departments, there may be an overestimation of the burden of systemic and osteoarticular 
symptoms. Patients referred to dermatologists may have less severe disease manifestations. 
However, retrospective studies are essential tools for the study of such rare diseases. They can 
also provide meaningful information regarding the efficacy and safety of therapeutic 
strategies in real life situations [39]. 
 As a whole, our data demonstrated the remarkable sustained efficacy of IL1Ra in 
SchS, as well as its favorable tolerance profile. We believe that every patient with SchS 
should have access to this drug [2]. However, whether every single patient with SchS should 
be convinced to be treated by an anti-IL-1 agent may be a matter of debate. In our view, the 
decision for recourse to this drug must be taken on an individual basis. Further studies are 
needed regarding the risk of AA amyloidosis in SchS, as well as on the influence of IL1Ra on 
the incidence of hematologic malignancies. 
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Table 1: Main characteristics of the 42 patients with Schnitzler’s syndrome throughout 
the course of the disease. 
 
 
  
 IL1Ra No IL1Ra Total  
 n = 29 n = 13 n = 42 p 
Age at disease onset, years 58.4 ± 12.4 63.2 ± 10.5 59.9 ± 11.9 0.2 
Sex, M/F 20/9 10/3 30/12 0.7 
Disease duration prior to diagnosis (months) 46 ± 39 36 ± 27 43 ± 36 0.4 
Disease manifestations (ever)     
  Rash 29 (100) 13 (100) 42 (100) 1 
  Fever 24 (83) 8 (61) 32 (76) 0.2 
  Pain (arthralgia or bone pain) 27 (93) 9 (69) 36 (86) 0.06 
  Weight loss (-10%) 19 (65) 6 (46) 25 (60) 0.3 
  Lymphadenopathy 8 (28) 5 (38) 14 (33) 0.5 
  Hepato- or splenomegaly 2 (7) 0 (0) 2 (5) 1 
  Bone lesion(s)
*
  24 (83) 8 (61) 32 (76) 0.2 
  Hemoglobin level, g/dL
**
 10.9 ± 1.7 11.2 ± 1.8  11.2 ± 1.7 0.6 
  CRP, mg/L
**
 132 ± 65 106 ± 60 124 ± 64 0.4 
Monoclonal component     
 IgM (overall) 26 (90) 11 (85) 37 (88) 0.6 
   IgM kappa 24 (83) 9 (69) 33 (78) 0.4 
   IgM kappa + other 1 (3) 1 (8) 2 (5)  
   IgM lambda 1 (3) 1 (8) 2 (5)  
 IgG 3 (10) 2 (15) 5 (12)  
The table represents the number (percentage) or mean ± standard deviation 
* Suggested by findings from a Te99 Bone scan in 27/36 (75%) or conventional radiographs in 17/34 (50%) 
** worst value recorded during the follow-up 
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Table 2: Treatments during the entire follow-up of the 42 patients with Schnitzler’s 
syndrome. 
  
Treatment n (%) 
NSAID 18 (43) 
Corticosteroids 29 (69) 
Immunomodulating agents 26 (62) 
 Colchicine 18 (43) 
 Hydroxychloroquine 8 (19) 
 Pefloxacin 8 (19) 
 Disulone 2 (5) 
 Thalidomide 1 (2) 
Immunosuppressants or Alkylating agents 13 (31) 
 Methotrexate 6 (14) 
 Azathioprine 3 (7) 
 Chlorambucil or Melphalan 5 (12) 
Non anti-IL-1 biologic 5(7) 
 Infliximab 3 (7) 
 Rituximab 1 (2) 
Anti-IL-1 29 (69) 
 Anakinra 29 (69) 
 Canakinumab 1 (2) 
NSAID: non steroidal anti-inflammatory drug 
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Table 3: Death in patients with Schnitzler’s syndrome: age, cause, and last treatments. 
  
Sex Age Cause of death SchS treatment 
M 77y Pneumonia, Severe pre-existing COPD IL1Ra (CR) 
M 86y Pneumonia, Severe pre-existing COPD IL1Ra (CR) 
F 80y Unknown IL1Ra (CR) 
F 77y Dementia Cs, 5mg/d (PR) 
COPD: chronic obstructive pulmonary disease ; Cs: Corticosteroids ; CR: complete remission ; PR: partial remission 
 
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
 22 
 
Figures  
 
 
Figure 1: Clinical manifestations according to the therapeutic regimen and response to 
IL1Ra. No IL1Ra: graph refers to information from the last follow-up. Before/under IL1Ra: 
graphs refer to the time of IL1Ra introduction (“before IL1Ra”) and last available information 
under IL1Ra treatment (“After IL1Ra”).  
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Figure 2: Biological findings and corticosteroid use according to the therapeutic regimen 
and response to IL1Ra treatment. No IL1Ra: graphs refer to information from the last 
follow-up. Before / under IL1Ra: graphs refer to the time of IL1Ra introduction (“before 
IL1Ra”) and last available information under IL1Ra treatment (“under IL1Ra”). The 
horizontal bars represent the median and interquartile range. 
***
p <0.0001. 
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Figure 3: Evolution of the monoclonal component level over time, with or without IL1Ra 
treatment. Longitudinal analysis of 10 SchS patients from Nantes University Hospital, 
treated with IL1Ra (n = 7, continuous line; month 0 refers to the date of the first IL1Ra 
injection) or untreated (n = 3, dashed line with open circles; month 0 refers to the first 
available serum electrophoresis). 
